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and platelets through integrin recognition. We find that the 
extracellular domain of human endoglin promotes specific 
platelet adhesion under static conditions and confers resist-
ance of adherent platelets to detachment upon exposure to 
flow. Also, platelets adhere to confluent endothelial cells in 
an endoglin-mediated process. Remarkably, Chinese hamster 
ovary cells ectopically expressing the human αIIbβ3 integ-
rin acquire the capacity to adhere to myoblast transfectants 
expressing human endoglin, whereas platelets from Glanz-
mann’s thrombasthenia patients lacking the αIIbβ3 integrin 
are defective for endoglin-dependent adhesion to endothelial 
cells. Furthermore, the bleeding time, but not the prothrom-
bin time, is significantly prolonged in endoglin-haplode-
ficient (Eng+/−) mice compared to Eng+/+ animals. These 
results suggest a new role for endoglin in αIIbβ3 integrin-
mediated adhesion of platelets to the endothelium, and may 
provide a better understanding on the basic cellular mecha-
nisms involved in hemostasis and thrombo-inflammatory 
events.
Keywords HHT · Hereditary hemorrhagic 
telangiectasia · TGF-β · RGD · Preeclampsia · CXCL12
Introduction
Endoglin (Eng; CD105) is a transmembrane glycoprotein, 
which is expressed by endothelial cells (EC), but not by 
platelets, and plays a critical physiological role in the car-
diovascular system [1–3]. It is an auxiliary receptor for the 
transforming growth factor β (TGF-β) family of proteins 
and has been shown to be essential for angiogenesis [4, 5]. 
The pathophysiological importance of endoglin in vascu-
lar biology is clearly established in humans by the linkage 
between heterozygous mutations in the endoglin gene and 
Abstract Complex interactions between platelets and acti-
vated endothelium occur during the thrombo-inflammatory 
reaction at sites of vascular injuries and during vascular 
hemostasis. The endothelial receptor endoglin is involved 
in inflammation through integrin-mediated leukocyte adhe-
sion and transmigration; and heterozygous mutations in the 
endoglin gene cause hereditary hemorrhagic telangiectasia 
type 1. This vascular disease is characterized by a bleeding 
tendency that is postulated to be a consequence of telangi-
ectasia fragility rather than a platelet defect, since platelets 
display normal functions in vitro in this condition. Here, 
we hypothesize that endoglin may act as an adhesion mol-
ecule involved in the interaction between endothelial cells 
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the occurrence of the hereditary hemorrhagic telangiecta-
sia (HHT) or Rendu–Osler–Weber syndrome [6]. HHT is 
considered a vascular disease that presents as epistaxis, 
mucocutaneous and gastrointestinal telangiectases, and 
arteriovenous malformations in the pulmonary, cerebral or 
hepatic circulation [7]. Recurrent nosebleeds, a major pre-
senting sign in HHT patients, can lead to chronic anemia and 
require blood transfusion [7, 8]. Endoglin was the first gene 
identified as being involved in HHT [6]. So far, more than 
500 different pathogenic mutations in endoglin have been 
reported, concerning up to 59% of the HHT patient popula-
tion, thus defined as the HHT1 subtype [9].
Pathogenic mechanisms in HHT are not completely 
understood, and the bleeding syndrome in patients is postu-
lated to be a consequence of a marked fragility of telangi-
ectases. Nonetheless, recent evidence suggests that HHT1-
associated mutations could affect other functions involving 
blood and vascular cells adhesion [10]. In HHT patients, 
blood parameters do not show prolonged coagulation time 
and prothrombin time is normal [11]. However, the mucocu-
taneous bleeding phenotype could also be due to a defect in 
primary hemostasis resulting from altered interactions of 
platelets with the (sub)endothelium. In this context, easy 
bruisability or post-operative wound healing defects in HHT 
are suggested by the recommendation of scrupulous dental 
hygiene and antibiotics prophylaxis prior to dental proce-
dures to avoid the risk of infections [7, 8]. In normal cir-
culation within intact vasculature, platelets barely undergo 
significant interaction with the endothelial surface. How-
ever, at sites of traumatic vascular injury, the subendothelial 
extracellular matrix (ECM) is exposed, allowing the prompt 
adhesion of platelets in order to limit hemorrhage, ensure 
coagulation and promote tissue healing [12–14]. Following 
de-endothelialization, initial platelet adhesion and spreading 
on vascular ECM components, such as collagen and von 
Willebrand factor (VWF), occur through engagement of 
glycoprotein VI (GPVI) and integrin α2β1, and GPIb-IX-V, 
respectively [15, 16]. Further stimulation of platelets leads to 
their aggregation largely through the activation of the αIIbβ3 
integrin and its capacity to bind fibrinogen that cross-links 
adjacent platelets [17]. Actually, the αIIbβ3 integrin can 
be activated by a variety of soluble molecules, including 
adenosine diphosphate (ADP), thrombin, as well as inflam-
matory cytokines such as CXCL12 (SDF-1α) [15, 16, 18, 
19]. Moreover, in inflammatory situations, activated EC can 
become pro-coagulant and pro-thrombogenic and can induce 
platelet adherence [20–24]. This thromboinflammatory 
process is not fully understood. As several other integrins, 
activated αIIbβ3 in platelets interacts with its many plasma 
or ECM adhesive ligands (fibrinogen, VWF, fibronectin, 
vitronectin) through recognition of specific sequences in 
the latter, including the canonical arginine–glycine–aspar-
tic acid (RGD) motif [17, 25]. It is, thus, of interest that 
the extracellular region of endoglin displays an RGD motif 
within the ZP-N subdomain [26], which is able to bind, at 
least, the α5β1 integrin on leukocytes and vascular mural 
cells upon stimulation of EC by the chemokine CXCL12 
[27, 28].
Our study was, thus, aimed to investigate a potential new 
function for endothelial endoglin based on the hypotheses 
that: (1) endoglin can be involved in platelet adhesion to the 
endothelium; (2) the RGD motif present in endoglin could 
be involved in this cell–cell interaction and platelet integ-
rins α5β1 and/or αIIbβ3, both RGD-binding integrins, be 
potential counter-receptors for endoglin; and (3) the process 
of platelet–endothelial cell interactions through an endog-
lin–integrin axis could be under an inflammatory control 
via the chemokine CXCL12 and its capacity to reinforce 
integrin stimulation.
Materials and methods
Human blood samples
Citrated blood samples were obtained from healthy donors, 
HHT1 patients (University Hospital, Salamanca, Spain) 
and Glanzmann’s thrombasthenia (GT) patients [29], who 
had not taken any medication for at least 10 days. The eth-
ics committee approved the study and all participants gave 
written informed consent. Whole blood was centrifuged for 
20 min at 100xg to obtain platelet-rich plasma (PRP). PRP 
was diluted with washing buffer (103 mM NaCl, 5 mM KCl, 
2 mM  CaCl2, 1 mM  MgCl2, 5 mM glucose and 36 mM cit-
ric acid; pH 6.5) and the platelet activation inhibitor PGE1 
(2 × 10−7 M) and the ADP scavenger apyrase (1 U/mL; 
Sigma-Aldrich) were added. Then, diluted PRP was centri-
fuged for 12 min at 1240×g to pellet the platelets. This wash-
ing step was repeated once, and the washing buffer always 
contained  PGE1 and apyrase [30]. Platelets were finally 
resuspended at 2.5 × 108/mL in Walsh’s buffer (137 mM 
NaCl, 20 mM PIPES, 5.6 mM dextrose, 1 g/L BSA, 1 mM 
 MgCl2, 2.7 mM KCl, 3.3 mM  NaH2PO4, pH 7.4). Prior to 
any experimental procedure, platelets were typically left 
at room temperature for 30 min. Under resting conditions, 
platelets did not show activation, as demonstrated by the lack 
of staining with an anti-CD62P antibody, a marker of inter-
nal storage organelles and their exocytosis during platelet 
activation. Platelets from GT patients failed to aggregate in 
response to agonists such as ADP, epinephrine, or collagen 
[29].
Cell lines and primary cultures
Human umbilical vein endothelial cells (HUVEC) and 
human aortic endothelial cells (HAEC) were grown in 
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EBM-2 medium, supplemented by EGM-2 SingleQuots 
(Lonza). Silencing of endoglin expression in EC, was car-
ried out by nucleofection or lipofection [28]. Generation of 
stable cell transfectants in L6E9 rat myoblasts, expressing 
either human L-endoglin or S-endoglin, and Chinese ham-
ster ovary (CHO) cells expressing either human αIIbβ3 or 
mutant αIIbβ3-P718 has been reported [31, 32].
Platelet adhesion assays
Plates and coverslips/chamber slides (Millicell EZ slide, 
Millipore) were coated with 100 µg/mL human fibrinogen 
(Calbiochem), 1% heat-inactivated BSA, or 7.5 µg/mL sol-
uble endoglin (sEng; extracellular domain Glu26-Gly586, 
R&D), and then blocked with 0.5% heat-inactivated BSA. 
Washed platelets were stained with 1 μM calcein (Invitro-
gen), and aliquots of  107 platelets/250 μL were added to 
wells of chamber slides. Calcein labeling was shown to nei-
ther induce nor alter the activation of platelets. After 5 min 
at 37 °C, Walsh’s buffer, supplemented with 1 mM  CaCl2, 
was added. After centrifugation at 800×g for 30 s, plates 
were incubated for 30 min, washed with PBS and platelet 
adhesion was quantified by fluorometry using a Varioskan 
equipment (Thermo Fisher Scientific). For platelet adhe-
sion to EC, calcein-stained platelets were added to HUVEC 
or HAEC monolayers in the presence/absence of CXCL12 
(200 ng/mL), RGD peptide (Arg–Gly–Asp; 1 mM), TRAP6 
(20 μM) or CXCR4 inhibitor AMD3100 (1 μM; Sigma-
Aldrich), and incubated for 10 min. Individual treatments 
of EC with CXCL12 or TRAP6 had no impact on endoglin 
expression levels. For adhesion to protein substrates, calcein-
stained platelets were incubated in the absence or presence 
of CXCL12, mouse monoclonal antibody (mAb) anti-αIIbβ3 
integrin (AP-2) [33], or an isotype-matched control IgG1 
(MOPC21, Sigma-Aldrich), as indicated. Binding of plate-
lets was quantified by measuring the fluorescence intensity 
profile using a fluorescence optical microscope (Observer 
D1, Zeiss) connected to a CCD camera (QIclick FCLR-12, 
Qimaging, Roper Scientific) and the ImageJ software.
Flow chamber assays
Microfluidic devices (Fluxion Biosciences or Maastricht 
Instrumentation) were used to evaluate shear-resistant plate-
let adhesion [27, 34]. The channels were primed and coated 
with 0.1% BSA, 7.5 µg/mL sEng or 100 µg/mL fibrinogen. 
Calcein-labeled platelets were perfused through the channels 
at 2 dynes/cm2, allowed to adhere in the absence of flow for 
10 min and then were subjected to 2 dynes/cm2 for 2 min. 
Similar experiments were performed using monolayers of 
HUVEC, HAEC, parental-L6E9, mock-L6E9, L-endoglin-
L6E9, and S-endoglin-L6E9 cells as coating [31]. Under 
our experimental flow conditions (2 dynes/cm2 for 2 min), 
no changes in endoglin protein levels were observed in 
endoglin-expressing cells. Platelet adhesion on HAEC was 
also performed in the presence of human sEng (1 μg/mL), 
AMD3100, RGD or CXCL12, as indicated above. Real-time 
platelet adhesion was recorded at 10× magnification using a 
fluorescence optical microscope (Observer D1, Zeiss) con-
nected with a CCD camera (QIclick FCLR-12, Qimaging, 
Roper Scientific). Flow rate was adjusted to 1 dyne/cm2 
(0.2 mL/min) and then increased at 2 dynes/cm2 for 2 min.
Mice and bleeding assays
All procedures were approved by the Committee for the Care 
and Use of Animals of the University of Salamanca and 
complied with the current guides of the European Union and 
the US Department of Health and Human Services for the 
Care and Use of Laboratory Animals. Endoglin heterozy-
gous (Eng+/−) mice [35] were backcrossed onto the C57BL/6 
background and genotyped as described [36]. The endog-
lin haploinsufficient mice with C57BL/6 background were 
selected because they do not show the classical HHT bleed-
ing phenotype [35], which may interfere with the bleeding 
time assays. To determine the tail bleeding time, animals 
were anesthetized with isoflurane, their tails were transected 
at 4 mm from the tip and immediately immersed in PBS at 
37 °C. The initial bleeding time, excluding animals with 
extreme bleeding, was 101.4 ± 66.19 s (n = 11) in Eng+/+ 
mice and 114.4 ± 78.94 s (n = 10) in Eng+/− mice, but in 
some cases rebleeding occurred following initial bleeding 
arrest. The total bleeding time, taking into account first 
bleeding plus rebleedings (when occurred), was measured. 
The percentage of animals with rebleedings that lasted 
longer than 2 min was also recorded. No rebleeding for 
5 min was considered as cessation of bleeding. Prothrom-
bin time and international normalized ratio were quantified 
using a portable coagulometer  (INRatio®2, Alere).
Immunofluorescence flow cytometry
For labeling of cell surface receptors, cells or platelets were 
incubated for 30 min with monoclonal antibodies anti-
GPIbα (Serotec; AK2), anti-αIIb (2BC1), anti-β3 (H1AG11) 
[37], anti-endoglin (Developmental Studies Hybridoma 
Bank-DSHB, Iowa; P4A4), or X63 (negative control), fol-
lowed by incubation with Alexa Fluor 488-anti-mouse IgG 
(Invitrogen). To detect the binding of soluble endoglin to 
platelets or CHO transfectants, with or without activation 
with 10 nM phorbol 12-myristate 13-acetate (PMA), sam-
ples were incubated 30–60 min with phycoerythrin-labeled 
sEng (PE-sEng; R&D/Immunostep) or with unlabeled sEng 
(R&D). The binding of unlabeled soluble endoglin to plate-
lets was followed by incubation with Alexa Fluor 488-con-
jugated anti-endoglin antibody (Invitrogen, MHCD10520). 
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All samples were analyzed with a Coulter Epics XL flow 
cytometer (Beckman Coulter).
Immunofluorescence microscopy
Samples were incubated with anti-β3 (H1AG11) or 
anti-tubulin (Sigma-Aldrich) murine monoclonal anti-
bodies and then with Alexa Fluor 488-anti-mouse IgG. 
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For staining of intracellular actin, adherent platelets on 
coated coverslips were incubated with Alexa Fluor 546 
conjugated to phalloidin (Invitrogen). For VWF staining, 
HAEC monolayers were incubated, first with a primary 
mouse antibody to VWF (Dako), and then with a Texas 
Red-labeled secondary antibody to mouse IgG (Vector). 
Binding of calcein-labeled platelets or CHO transfectants 
was carried out as described above. Samples were ana-
lyzed using the Leica TCS-SP2-AOBS confocal micro-
scope system.
Western blot analysis
L6E9 myoblasts expressing either human L-endoglin or 
S-endoglin were lysed on ice-cold lysis buffer (10 mM 
Tris–HCl pH 8, 150 mM NaCl, 1% NP-40, and a cock-
tail of protease and phosphatase inhibitors; Roche) and 
protein concentrations were determined (Bradford, Bio-
Rad). Lysate aliquots containing equal amounts of pro-
tein were separated by SDS-PAGE and electrotransferred 
onto PVDF membranes (Millipore). Immunodetection 
was carried out by probing the membrane with mouse 
monoclonal antibodies anti-endoglin (DSHB; P3D1) or 
anti-β-tubulin (Calbiochem), as a loading control, fol-
lowed by incubation with the corresponding horseradish 
peroxidase-conjugated secondary antibody. Protein bands 
were revealed using the SuperSignal chemiluminescent 
substrate (Pierce).
Quantification and statistical analysis
All the assays were performed in triplicate and repeated at 
least twice. Values are expressed as mean ± standard error 
of the mean (SEM). Data from in vivo experiments are rep-
resented as box-plots. Multiple comparison data were ana-
lyzed using one-way ANOVA with post hoc Bonferroni and 
Scheffe tests. Direct group–group comparisons were carried 
out using independent Student’s t tests with prior Levene 
tests for equality of variances. p < 0.01 and p < 0.05 were 
considered statistically significant, and p < 0.005 was con-
sidered highly statistically significant.
Results
Pro‑adhesive activity of endoglin on platelets in vitro
To analyze the effects of endoglin on platelet adhesiveness 
under static conditions, plates were coated with sEng or 
fibrinogen, a well-known adhesive protein for platelets [38]. 
Endoglin coating markedly enhanced platelet adhesion with 
a significant ~ 3-fold increase over nonspecific adhesion to 
BSA (Fig. 1a, first upper row, c). Adhesion on endoglin was, 
however, lower than that measured on fibrinogen, which 
showed a ~ 9-fold increase over BSA. Interestingly, on BSA 
coating the few bound platelets appear to be non-activated as 
evidenced by the presence of intact microtubule rings and no 
rearrangement of the actin cytoskeleton (Fig. 1a; see green 
stain in third row and red stain in second row, respectively, 
as well as merge on fourth row). However, on fibrinogen or 
endoglin coating, adherent platelets were found to be acti-
vated, as shown by the presence of widespread microtubule 
rings, as well as by filopodia, lamellipodia and stress fib-
ers. In the case of fibrinogen, a lack of correlation between 
tubulin-ring and actin staining was observed, a finding likely 
due to the fact that fibrinogen induces a strong activation 
platelets promoting depolymerization of tubulin subunits 
and loss of tubulin ring-shaped structures. Most of the plate-
lets adherent to fibrinogen under static conditions are spread 
and sometimes adherent to one another, whereas there were 
fewer adherent and fully spread platelets on endoglin, sug-
gesting that the mechanism of platelet adherence to fibrino-
gen or endoglin seems substantially different (see “Discus-
sion”). Of note, on endoglin coating an increased ratio of 
lamellipodia/filopodia was observed (Supplemental videos 
#1, 2, 3).
Resistance to flow-induced detachment of platelets adher-
ing on endoglin-coated surfaces was also explored. Platelets 
were perfused into flow chambers and allowed to adhere to 
the substrate under static conditions for 10 min and, then, 
subjected to flow at 2 dynes/cm2 for 2 min (Fig. 1b and sup-
plemental videos 4–6). Under this setting, the number of 
Fig. 1  Platelet adhesion on endoglin-coated wells. a Platelets resus-
pended in Walsh’s buffer were incubated for 30  min in endoglin-, 
fibrinogen- or BSA-coated wells. After washing the plates, plate-
lets were labeled with an anti-β3 integrin subunit antibody (green 
fluorescence), or with phalloidin (red fluorescence) and anti-tubulin 
antibody (green fluorescence), as described under “Materials and 
methods”. The zoom of merged phalloidin and tubulin staining is 
shown in the lower row. Scale bars, 10 µm. Quantification of plate-
lets labeled with the anti-β3 was performed using ImageJ software 
and is shown in c. Mean values ± SEM of three different preparations 
of platelets each tested in triplicate are displayed. Significant differ-
ences were observed between endoglin or fibrinogen coating and 
BSA control substrate (**p < 0.005; *p < 0.05). b Platelet adhesion 
under flow was assessed using the microfluidic system of BioFlux, 
as described under “Materials and methods”. Calcein-labeled plate-
lets were perfused in flow chambers coated with the indicated pro-
teins, allowed to adhere in the absence of flow for 10 min, and then 
subjected to 2 dynes/cm2 for 2 min. Platelets bound to the substrate 
were visualized by microscopy. Scale bars, 60 µm. Quantification of 
platelet adhesion was performed using ImageJ software and is shown 
in d. Mean values ± SEM of three different preparations of platelets 
each tested in triplicate are displayed. Significant differences were 
observed between endoglin or fibrinogen coating and BSA control 
substrate (***p < 0.001; **p < 0.005). Of note, due to the different 
experimental conditions, adhesion values obtained under static (c) or 
flow conditions (d) are not comparable. AU arbitrary units
◂
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adherent platelets on endoglin or fibrinogen was significantly 
increased by ~ 7-fold or ~ 14-fold, respectively, as compared 
to adhesion on BSA (Fig. 1d). Of note, a shear stress of 
2 dynes/cm2 is within a physiological range, which may vary 
from 0.4 dynes/cm2 (small veins) to 20 dynes/cm2 (peak 
flow in abdominal aorta) [27]. Within this range, low shear 
stress values are expected to occur in small telangiectases of 
mucosal membranes, which bleed upon rupture in HHT [7].
Pro‑adhesive activity of endothelial endoglin
The above results are suggestive of a potential role of endog-
lin as an adhesive protein for platelets, but do not necessarily 
imply that endoglin expressed at the EC surface supports 
platelet adhesion. Thus, platelet adhesion was evaluated on 
monolayers of cultured EC, which constitutively express 
endoglin [2, 28]. As indicated in Fig. 2a and supplemental 
Fig. 1A, B, platelets slightly adhered under static conditions 
to EC of either venous (HUVEC) or arterial (HAEC) origin. 
However, this adhesion was markedly enhanced by ~ 5-fold 
and ~ 3.5-fold on HAEC and HUVEC, respectively, when 
the integrin-activating chemokine CXCL12 was added to the 
culture medium. Platelet adhesion to EC was also assayed 
under shear stress applied to adherent platelets (supplemen-
tal Fig. 1C, D, and supplemental videos 7 and 8), showing 
again that the presence of CXCL12 increased the number 
of adherent platelets by ~ 2.5- to ~ 3.5-fold over untreated 
samples. As expected, an increase of platelet adhesion to 
HAEC was also observed in the presence of the PAR-1 
activating peptide TRAP6, a well-known platelet activator 
[15, 21] (Fig. 2a). Under these conditions, the CXCL12-
dependent adhesion of platelets was indeed inhibited by the 
chemokine receptor (CXCR4) inhibitor AMD3100, but, 
interestingly, also by the RGD peptide (Fig. 2b). VWF is 
one RGD-type adhesive protein that can be secreted by acti-
vated EC and that can allow adherence of platelets on their 
surface [21, 22]. Of note, cells exposed to CXCL12 showed 
a basal labeling of VWF similar to that seen with unstimu-
lated cells, whereas TRAP6 induced a substantial increase 
of membrane-associated VWF (Supplemental Fig. 2). These 
results suggest that CXCL12 is not a trigger for VWF secre-
tion under our experimental conditions, and that increased 
expression of VWF is not involved in the CXCL12-stimu-
lated adhesion of platelets to EC.
Using flow cytometry, we previously reported that HAEC 
and HUVEC express high and similar levels of endoglin, 
whereas endoglin expression was markedly reduced in EC 
nucleofected with endoglin-specific siRNA, but not with a 
scrambled, negative control siRNA [28]. Moreover, endog-
lin-silenced EC could return to normal levels of endoglin 
expression upon rescue with the endoglin expression vector 
pCEXV-EndoL [28]. Thus, a role for endoglin in the adher-
ence of platelets to EC as described above could be inferred 
from the following observations. Firstly, endoglin silenc-
ing in HUVEC or addition to the medium of either sEng, 
as a competitor for membrane-bound endothelial endog-
lin, or the blocking anti-endoglin mAb P4A4, all markedly 
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Fig. 2  Effect of CXCL12 and TRAP6 on platelet adhesion to 
endothelial cells. a Calcein-labeled platelets were incubated for 
10 min on HAEC monolayers in the absence or presence of CXCL12 
or thrombin receptor activating peptide 6 (TRAP6) and washed 
twice with PBS. Adhesion of platelets to EC was visualized by flu-
orescence microscopy (×20 magnification) (top panels). Scale bars, 
40 µm. Quantification of platelet adhesion repeated in quadruplicates 
with two different platelet preparations and analyzed by ImageJ soft-
ware is shown in the histogram. Mean values ± SEM are displayed. 
**p < 0.01; *p < 0.05. b Calcein-labeled platelets were incubated for 
10 min on HAEC monolayers in the absence (control) or presence of 
CXCL12, either alone or with the RGD peptide, the CXCR4 inhibi-
tor AMD3100, or the recombinant extracellular part of endoglin (Sol.
Eng), as indicated. Platelets were visualized by fluorescence micros-
copy and quantified (quadruplicates with two different platelet prep-
arations) with ImageJ software. Mean values  ±  SEM are displayed. 
**p < 0.005; *p < 0.01
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and significantly (p < 0.001) inhibited the adherence of 
platelets to HAEC or HUVEC in the presence of CXCL12 
(Figs. 2b, 3a, b). As measured under static conditions, a 
reduction of ~ 70–80% in the number of adherent platelets 
was found when membrane-bound endothelial endoglin was 
suppressed/neutralized as compared to untreated HUVEC 
(Fig. 3b). Interestingly, silencing endoglin expression also 
significantly reduced by ~ 80% the adherence of platelets 
to HUVEC in the absence of CXCL12 stimulation. In addi-
tion, upon CXCL12 stimulation, combining endoglin silenc-
ing with competition or blockade of residually expressed 
endothelial endoglin with sEng or the anti-endoglin mAb 
reduced the number of adhering platelets on HUVEC to less 
than 10% of control values (Fig. 3b). This residual endoglin-
independent binding of platelets to EC probably involves 
other adhesion molecules, including VWF, which can be 
spontaneously released during culture of EC (Supplemental 
Fig. 2), and various platelet membrane receptors [21, 22]. 
The role of endoglin in platelet–EC interaction was con-
firmed when looking at the resistance of adherent platelets to 
detachment upon exposure to flow (Fig. 3c and supplemental 
videos #9–12). In these experiments, we used either endog-
lin-silenced HAEC or cells previously exposed to sEng that 
acts as an endoglin competitor. Platelets remaining adherent 
to HAEC under flow in the presence of CXCL12 were sig-
nificantly (p < 0.005) reduced by ~ 70% upon silencing of 
endoglin expression, and by approximately 60% in the pres-
ence of sEng (Fig. 3c). In the absence of CXCL12, silencing 
endoglin expression also reduced by ~ 40% (p < 0.005) the 
number of platelets that adhered to HAEC. Restoring endog-
lin expression in endoglin-silenced HAEC using an endoglin 
expression vector allowed the recovery of normal values of 
platelet adhesion to either unstimulated or CXCL12-stimu-
lated samples (pEng, Fig. 3c, d). Of note, individual treat-
ments of HAEC with CXCL12 had no impact on endoglin 
expression levels (data not shown).
Next, we used the rat myoblast cell line L6E9-P as another 
cellular model, since these cells do not express endoglin, 
but can be stably transfected with the long (L6E9-L) or the 
short (L6E9-S) form of human endoglin [31]. These cell 
transfectants may serve to assess not only the role of the 
extracellular domain, shared by both isoforms, but also the 
putative role of the cytoplasmic domain, which markedly 
differs in length, amino acid composition and phosphoryla-
tion status between L-endoglin and S-endoglin [2]. We, thus, 
compared the adhesion of platelets to monolayers of paren-
tal, untransfected (L6E9-P) or mock-transfected (L6E9-M) 
cells, with adhesion to cells expressing either one of the 
two endoglin isoforms (L6E9-L or L6E9-S). Stimulation 
with CXCL12 did not allow noticeable platelet adhesion 
under flow to either L6E9-P or L6E9-M cells. However, and 
similar to results obtained with EC, it induced a significant 
(p < 0.005) and marked platelet adhesion to L6E9-L and 
L6E9-S cells, with a seven- to eightfold increase over base-
line values (Fig. 4a, see dark green bars). L- and S-endoglin 
in transfected L6E9 cells could be detected to similar levels 
by Western blot analysis, while showing a slight molecular 
mass difference between both isoforms (Fig. 4b), as reported 
[31].
Platelet αIIbβ3 integrin is involved 
in endoglin‑mediated adhesion to endothelial cells
In search for counter-receptor(s) on platelets that could 
interact with endothelial endoglin, and given that we have 
previously demonstrated that the endoglin RGD motif is 
involved in integrin-mediated cell adhesion to EC [27, 28], 
we focused our attention on the αIIbβ3 integrin, a major 
RGD-dependent adhesive receptor in platelets [17, 25]. We 
performed flow chamber adhesion assays using our several 
L6E9 cell subtypes as adherent cell monolayers, and CHO 
cells either negative for human αIIbβ3 (wild-type CHO) 
or transfected to express human αIIbβ3 (CHO-αIIbβ3), as 
flowing cells. Under our experimental conditions, wild-type 
parental CHO cells never displayed adhesion to any of the 
L6E9 cell monolayers (data not shown). However, expres-
sion of human endoglin in L6E9-L or L6E9-S promoted 
adhesion of CHO-αIIbβ3 cells in the presence of CXCL12 
(Fig. 4a–c). To confirm that endoglin is able to bind αIIbβ3 
integrin, we performed binding assays using confocal 
microscopy and flow cytometry analysis of CHO cell lines 
exposed to phycoerythrin (PE)-labeled sEng (Supplemental 
Fig. 3). The extracellular domain of endoglin was able to 
bind CHO-αIIbβ3 cells upon their stimulation with PMA, 
as well as CHO cells expressing a constitutively activated 
αIIbβ3 integrin (CHO-αIIbβ3-P718) [32], but not αIIbβ3-
negative CHO cells (Supplemental Fig. 3A). Flow cytometry 
analysis also revealed PE-sEng binding in PMA-stimulated 
CHO-αIIbβ3 cells, and in unstimulated CHO-αIIbβ3-P718 
cells, but not in parental CHO (Supplemental Fig. 3B). Fluo-
rescence was extensively reduced in the presence of a tenfold 
molar excess of unlabeled sEng, supporting binding specific-
ity. Moreover, binding of unlabeled sEng to PMA-stimulated 
platelets was evidenced using a fluorochrome-conjugated 
antibody against endoglin (Supplemental Fig. 3C).
Additional evidence for the interaction between the 
platelet αIIbβ3 integrin and endoglin was obtained from 
experiments of platelet adhesion to endoglin-coated plates 
(Fig. 4d, e). In these assays, we used the antibody AP-2 to 
αIIbβ3 integrin, which has been reported to block fibrino-
gen-dependent platelet aggregation [33], as well as platelet 
adhesion to immobilized substrates such as fibrinogen [39]. 
Thus, we found that binding of platelets to endoglin was 
clearly inhibited by addition of the blocking antibody AP-2 
to the αIIbβ3 integrin, as compared to a control mouse IgG1 
(Fig. 4e).
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Finally, a major role of the platelet αIIbβ3 integrin in 
the process of endoglin-dependent platelet adhesion to 
EC was supported by the use of platelets from two Glan-
zmann thrombasthenic (GT) patients [29]. Flow cytometry 
analysis of the major membrane adhesive receptor subunits 
GPIα, αIIb and β3 indicated normal levels of GPIα in GT 
as compared to control normal platelets, while GT plate-
lets showed a drastic reduction in the expression levels of 
both αIIb and β3 subunits (Fig. 5a). In static adhesion assays 
using HUVEC monolayers, GT platelets in the presence of 
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CXCL12 showed a significant ~ 70% reduction of adher-
ence as compared to normal platelets (Fig. 5b, c). In the 
same assay, platelets from three different HHT1 patients 
expressing normal levels of αIIbβ3 integrin (Fig. 5a) showed 
a normal level of adhesion to HUVEC (Fig. 5b, c). In addi-
tion, binding of GT platelets to endoglin-coated plates was 
markedly decreased as compared to platelets from normal 
subjects or HHT1 patients, this difference being enhanced in 
the presence of CXCL12 (Fig. 5d, e). Together, these results 
suggest that endoglin can interact with αIIbβ3 integrin pre-
sent on platelets.
Endothelial endoglin‑deficient mice exhibit an increased 
bleeding time
Endoglin heterozygous mice (Eng+/−) represent a model of 
HHT1 [35]. Endoglin haploinsufficiency in these mice is 
confirmed by a reduction of ~ 35–65% in the amount of 
endoglin protein in highly vascularized tissues (lungs and 
kidneys) and ~ 50% in cultured aortic EC [40, 41]. We 
observed that Eng+/− mice in C57BL/6 background had 
significantly prolonged bleeding times as compared to 
wild-type Eng+/+ animals (initial bleeding plus rebleed-
ings) (Fig. 6a), as well as an increased number of animals 
with long rebleedings [5/10 Eng+/− mice (50%) vs 3/11 
Eng+/+ mice (27.27%)] (Fig. 6b). However, no differences 
in prothrombin time between Eng+/− and wild-type mice 
were found (Fig. 6c), in agreement with published data from 
HHT1 patients [11]. Because Eng+/− C57BL/6 mice do not 
show evident vascular anomalies [35, 36, 41], their increased 
bleeding time cannot be explained by the presence of HHT-
like vascular lesions, but likely by their endoglin haploinsuf-
ficiency in the endothelium. Taken together, these results 
are compatible with the potential involvement of endothelial 
endoglin in primary hemostasis.
Discussion
Intricate interactions between circulating platelets and an 
activated microvascular endothelium are at the basis of the 
thrombo-inflammatory reaction seen at sites of vascular 
injuries accompanying many pathophysiological situations 
[13, 20], and are likely an early step during vascular hemo-
stasis [23, 24]. However, these interactions still remain to 
be fully characterized at the molecular level. Focal interac-
tion of (activated) platelets with an (activated) endothelial 
surface was initially proposed to be mediated by activation 
of the coagulation, and/or the dampening of the anticoagu-
lation, anti-platelet, and fibrinolytic cascades on EC, thus 
allowing the formation of an endothelium-associated fibrin 
network able to entrap platelets [42–44]. However, platelets 
and EC may also show direct interactions through engage-
ment of adhesion receptors, counter-receptors, and ligands, 
that allow platelets to first roll, then adhere and possibly 
aggregate on the endothelial surface [45–47]. It is com-
monly accepted that subsequent to rolling, firm adhesion of 
platelets to EC and accompanying platelet activation occurs 
mainly via the engagement of integrins on both sides, the 
αVβ3 on EC and the αIIbβ3 on platelets that can bind several 
RGD-type adhesive proteins acting as bridging molecules 
between the two cell types [21–23, 48].
A potential new partner in platelet–EC interactions is now 
emerging, as our data support the involvement of endothe-
lial endoglin in platelet adhesion to endothelium through 
a process that clearly implicates platelet αIIbβ3, the quan-
titatively predominant integrin family member in platelets 
[49, 50], as a counter-receptor (Fig. 7). Thus, platelets could 
specifically adhere to purified, immobilized endoglin, and a 
drastic reduction of platelet adhesion to EC was observed 
when endoglin was silenced with siRNA or in the presence 
of either sEng, the extracellular part of endoglin containing 
the RGD motif, or the anti-endoglin P4A4 antibody. Moreo-
ver, the effect of endoglin silencing was rescued with the 
ectopic expression of endoglin. Finally, the specific involve-
ment of endoglin in platelet adhesive function is also sup-
ported by experiments using myoblast transfectants overex-
pressing cell surface human endoglin. Recent studies have 
shown that endoglin binds to integrins on leukocytes and 
Fig. 3  Effect of endoglin silencing on adhesion of platelets to EC. a 
Static adhesion of platelets to HUVEC. Platelets labeled with calcein 
were incubated for 10 min on HUVEC monolayers, previously treated 
with a siRNA specific for endoglin or with a scrambled siRNA, as 
described under “Materials and methods”. Incubation was carried out 
in the absence or presence of CXCL12 (100  ng/mL), sEng (50  ng/
mL), or the anti-endoglin mAb P4A4. After washing twice with 
PBS, adhesion under static conditions was visualized by fluorescence 
microscopy (×20 magnification). Scale bars, 40  µm. b Quantifica-
tion of platelet adhesion shown in a repeated in triplicates with two 
different platelet preparations and analyzed using ImageJ software. 
Mean values ± SEM are displayed. **p < 0.005; *p < 0.05. c Plate-
let adhesion under flow was assessed using a Maastricht Instrumen-
tation equipment. Calcein-labeled platelets were perfused in flow 
chambers coated with HAEC, previously untreated or treated with 
siRNA specific for endoglin, in the presence of CXCL12 or sEng, 
as indicated. Rescue experiments of endoglin expression were per-
formed by nucleofection of HAEC with the endoglin expression vec-
tor pCEXV-EndoL (pEng). Platelets were allowed to adhere in the 
absence of flow for 10  min, and then subjected to 2  dynes/cm2 for 
2  min. Quantification of platelet adhesion (triplicates with two dif-
ferent platelet preparations), was performed using ImageJ software. 
Mean values ± SEM are displayed. **p < 0.005; *p < 0.05. d HAEC 
were nucleofected with siRNA specific for endoglin (siEng) or with 
a scrambled siRNA (control siRNA), as indicated. Rescue experi-
ments of endoglin expression were performed by nucleofection of 
HAEC with the endoglin expression vector pCEXV-EndoL (pEng). 
The expression levels of endoglin were determined by immunofluo-
rescence flow cytometry using specific antibodies prior to adhesion 
experiments shown in c. The vertical blue line indicates the fluores-
cence intensity of HAEC stained with an irrelevant isotype-matched 
control antibody
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vascular mural cells via its RGD motif [27, 28]. Integrin 
αIIbβ3 is a receptor for fibrinogen, VWF, fibronectin and 
vitronectin, involving their RGD motifs and contributes to 
platelet activation. Using several cell transfectants express-
ing either αIIbβ3 integrin or endoglin, we now demonstrate 
the specific interaction between αIIbβ3 and endoglin under 
shear stress conditions. Also, the specific binding of sEng 
to CHO cells expressing human αIIbβ3 is shown in the pre-
sent work, whereas platelets from GT patients, which exhibit 
a deficient expression of αIIbβ3 integrin, display a strong 
reduction of adhesion to endoglin-coated plates, as well as 
to endoglin-expressing EC, compared to control platelets. 
The low level of residual adhesion shown by GT platelets 
(see Fig. 5) could be due to other adhesion molecules and 
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cell receptor pairs, such as secreted VWF, the GPIb-V-IX 
complex, or αvβ3 or α5β1 integrins [21, 22, 48]. In this 
regard, we have already demonstrated that α5β1 integrin 
is involved in endoglin-mediated adhesion [27]. Although 
the RGD-dependent integrin α5β1 is present on platelets 
and supports their adhesion to fibronectin, it is expressed at 
much lower levels than αIIbβ3 [49, 50]. Interestingly, adhe-
sion of normal platelets to an endoglin-coated surface led 
to the formation of lamellipodia, as well as to a widespread 
of the microtubule ring, both processes being the conse-
quence of the integrin-mediated activation of platelets [51, 
52]. However, we noted a differential behavior of platelet 
adherence to fibrinogen or endoglin that is likely related 
to the fact that fibrinogen is an hexamer with at least four 
integrin-binding motifs (two at each end, one RGD and one 
dodecapeptide) that would allow full outside–in signaling 
and clustering of integrins, whereas endoglin is a dimeric 
protein with only two RGD integrin-binding motifs. These 
differences in adherence may reflect the existence of distinct 
binding affinities and specificities of these ligands to αIIbβ3 
and other platelet integrins.
On circulating platelets in vivo, the αIIbβ3 integrin is in 
an inactive form, thus preventing spontaneous platelet aggre-
gation in the circulation. However, upon platelet activation at 
sites of vascular injury, αIIbβ3 is readily activated for ligand 
binding, enabling the formation of hemostatic plugs [38, 50]. 
This is in line with our results showing that: (1) treatment 
of platelets with the PAR-1-activating peptide TRAP6 or 
with CXCL12 stimulates platelet adhesion to EC, while 
treatment of platelets with CXCL12 enhances the binding 
of platelet αIIbβ3 to endoglin in static and flow conditions; 
and (2) constitutively activated αIIbβ3 integrin (mutant 
P718) and wild-type αIIbβ3 activated with phorbol esters 
in CHO cells show an enhanced binding to sEng. Several 
studies have demonstrated the CXCL12-induced activation 
of platelets [18, 53–55], including their increased adherence 
to EC under flow conditions [56]. Moreover, the involve-
ment of the CXCL12/CXCR4/CXCR7 signaling axis in the 
activation of platelet integrins is in agreement with: (1) the 
presence of the CXCL12 receptors CXCR4 and CXCR7 in 
the platelet membrane [19, 57]; (2) the recent observations 
that CXCL12 is an autocrine activator of platelets [19, 58]; 
and (3) the depletion of CXCR4 in mice results in smaller 
thrombi [59]. Thus, once activated under an inflammatory 
environment, platelet integrins may bind to endothelial 
endoglin (Fig. 7). Supporting this view, endoglin has been 
shown to be upregulated in vivo in several inflammatory set-
tings, including wound healing, atherosclerosis and chronic 
kidney disease [60–62]. Interestingly, high plasma levels of 
a soluble form of endoglin are found in patients with preec-
lampsia, a leading cause of maternal and prenatal morbidity 
associated with systemic hypertension, chronic inflammation 
and thrombocytopenia [63–66]. This soluble form of endog-
lin is thought to be released from membrane-bound endoglin 
upon the proteolytic action of the metalloprotease MMP-
14 [67–69]. Because soluble endoglin has been postulated 
to have a pathogenic role in preeclampsia [63, 68, 70] and 
retains its capacity to bind integrins ([27, 28]; this work), it 
will be interesting to explore whether soluble endoglin has 
an impact on platelet function in this disorder.
Together, the above data suggest a close physical and 
functional association between endoglin on EC, and the 
αIIbβ3 integrin on platelets, that could be central in the inter-
actions between the two cell types in a thrombo-inflamma-
tory context (Fig. 7). Platelet–EC physical interactions share 
many features with leukocytes interacting with an inflam-
matory endothelium in the process of extravasation [46, 47, 
71, 72]. As mentioned above, platelets first tether and roll 
on the endothelium, then arrest, firmly adhere, spread, and 
finally get fully activated [46, 47]. After the initial tethering 
and rolling steps [21, 23, 24, 73], arrest and firm adhesion, 
including spreading of platelets to EC appear to essentially 
implicate the αIIbβ3 integrin on the platelet side, while sev-
eral counter-receptors have been identified on activated EC. 
The latter include the αVβ3 integrin, with bridging of the 
two integrins by their shared, RGD-type adhesive proteins 
fibrinogen and/or VWF, as well as intercellular adhesion 
molecule-1 (ICAM-1) through bridging by fibrinogen [22, 
48, 74]. Remarkably, however, the combination of blocking 
antibodies targeting simultaneously the αVβ3 integrin and 
Fig. 4  Involvement of αIIbβ3 integrin in endoglin-mediated cell 
adhesion. a Adhesion of platelets and CHO-αIIbβ3 cells to endoglin-
expressing cells was measured under flow. Calcein-labeled plate-
lets or CHO-αIIbβ3 cells were perfused in flow chambers previ-
ously coated with parental (L6E9-P), mock-transfected (L6E9-M), 
L-endoglin-transfected (L6E9-L) or S-endoglin-transfected (L6E9-S) 
cells in the absence or presence of CXCL12, allowed to adhere in the 
absence of flow for 10  min, and then subjected to 2  dynes/cm2 for 
2 min. Quantification of adhesion, repeated in triplicates with differ-
ent platelets (dark green) or CHO cells (light green) preparations, was 
performed by ImageJ software. Mean values  ±  SEM are displayed. 
**p < 0.005; NS not significant. Parallel experiments using calcein-
labeled CHO wild-type cells did not show any significant adhesion 
to endoglin-expressing L6E9 transfectants (fluorescence levels  <  2; 
data not shown). b Western blot analysis of endoglin in L6E9 mock, 
L-endoglin (L-Eng) and S-endoglin (S-Eng) transfectants, using 
tubulin as a loading control. c Representative experiment of adhe-
sion of calcein-labeled CHO-αIIbβ3 cells to flow chambers coated 
with mock-transfected cells (L6E9-M) or L-endoglin-transfected cells 
(L6E9-L), performed as described in a and visualized by fluorescence 
microscopy (×10 magnification). Scale bars, 20  µm. d, e Platelet 
adhesion to endoglin is inhibited by anti-β3 antibodies. Plates coated 
with BSA or endoglin were incubated with calcein-labeled platelets 
for 15  min in the absence (−) or in the presence of an anti-αIIbβ3 
integrin mAb or an isotype-matched control IgG1. After washing 
with PBS, plates were visualized by fluorescence microscopy (×10 
magnification). Scale bars, 40 µm (d). Quantification of adhesion was 
performed using ImageJ software (e). Background adhesion values 
of BSA-coated wells were subtracted from those of endoglin-coated 
wells. Mean values ± SEM are displayed. **p < 0.005
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Fig. 5  Adhesion of platelets from patients with GT or HHT1 dis-
eases. a Integrin expression in platelets from normal subjects, and GT 
and HHT1 patients was analyzed by flow cytometry using anti-GPIα 
(AK2), anti-αIIb (2BC1), and anti-β3 (H1AG11) mAbs. As a nega-
tive control, non-specific IgG (X63) was used. Representative his-
tograms are shown and illustrate a deficient αIIbβ3 integrin expres-
sion in GT platelets, whereas the GPI-V-IX complex is expressed to 
normal levels. b, c Adhesion of platelets from normal subjects, and 
GT and HHT1 patients to HUVEC monolayers. Calcein-labeled 
platelets were incubated for 15  min on HUVEC monolayers in the 
presence of CXCL12. After washing three times with PBS, repre-
sentative samples were visualized by fluorescence microscopy (×20 
magnification). Scale bars, 40 µm (b). Each platelet preparation from 
patients or control subjects was analyzed twice (in consecutive days) 
using three replicates each time (normal subjects, n = 10; GT, n = 4; 
HHT1, n  =  6). Quantification of adhesion was performed using 
ImageJ software (c). Mean values ± SEM are displayed. **p < 0.005. 
d, e Adhesion of platelets from normal subjects, and GT and HHT1 
patients to endoglin substrate. Plates coated with BSA, endoglin, or 
endoglin plus CXCL12 were incubated with calcein-labeled plate-
lets for 15  min. After washing with PBS, plates were visualized by 
fluorescence microscopy (×20 magnification). Scale bars, 40 µm (d). 
Each platelet preparation from patients or control subjects was ana-
lyzed twice (in consecutive days) using three replicates each time 
(normal subjects, n  =  10; GT, n  =  4; HHT1, n  =  6). Quantifica-
tion of adhesion was performed using the Varioskan equipment (e). 
Background adhesion values of BSA-coated wells were subtracted 
from those of endoglin-coated wells. Not significant differences were 
observed between HHT1 and normal platelets. Mean values ± SEM 
are displayed. **p < 0.005; *p < 0.01
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ICAM-1 on EC appears to reduce the platelet–EC interaction 
by no more than 50% [22], suggesting that other endothelial 
receptor(s) could be involved in the final step of firm platelet 
adherence and spreading. Based on our present observation, 
endoglin is likely to be one such receptor, and it is of note 
that, under our experimental conditions, blocking endothe-
lial endoglin expression almost completely abrogated the 
firm adhesion of platelets to EC and their resistance to 
detachment under flow.
Although endoglin is a TGF-β co-receptor, in this work 
we have not explored whether endoglin-dependent adhesion 
to integrins is mediated by TGF-β signaling. Nonetheless, 
several lines of evidence suggest that these are two inde-
pendent processes. First, integrins bind to the RGD-con-
taining zona pellucida domain (ZPD) [27, 28], whereas the 
physiological ligand BMP9, a member of the TGF-β family, 
binds to the orphan domain (OD); and both ZPD and OD 
are in separate regions of the extracellular part of endoglin 
[75]. Second, cells overexpressing L-endoglin or S-endoglin 
show a similar level of integrin-dependent binding (Fig. 4), 
in spite of the fact that these isoforms contribute to opposite 
TGF-β signaling pathways mediated by the type I receptors 
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deficient mice. a Total bleeding time (initial bleeding plus rebleed-
ings) in Eng+/− mice (n = 10) is significantly longer (*p < 0.05) than 
that of Eng+/+ animals (n = 11). The mean bleeding time of Eng+/+ 
mice was taken as a reference and each measurement was expressed 
as percentage of this value. b Rebleeding was assessed following ini-
tial bleeding arrest. A total of 11 Eng+/+ and 10 Eng+/− mice were 
used and the percentage of animals showing rebleeding longer than 
2 min is shown. c Prothrombin time in Eng+/− mice (n = 10) is not 
significantly different from control animals (n  =  11). s seconds. 
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Fig. 7  Role of endothelial endoglin in platelet adhesion to the 
thrombo-inflammatory endothelium. The schematic diagram focuses 
on a hypothetical model for endoglin-mediated adhesion of platelets 
to the (micro)vascular endothelium. a Under normal conditions, cir-
culating platelets do not adhere to a quiescent endothelium, which 
displays anti-thrombotic properties, tightened junctions and acts as 
an anti-hemorrhagic barrier. b On inflammatory stimulation, the 
endothelium shifts to a pro-thrombotic state, shows loosened junc-
tions and behaves as a leaking barrier. Under this setting, EC release 
different soluble factors, including adenosine 5′-diphosphate (ADP), 
thrombin (Thr) and the chemokine CXCL12, leading to activation of 
platelet integrin αIIbβ3. In turn, activated integrin αIIbβ3 can bind to 
endoglin on EC, allowing adhesion of platelets to the endothelium. 
The presence of the juxtamembrane RGD motif within endoglin 
is indicated as a brown sphere. The involvement of other adhesion 
receptors on both cell types, such as those described in the text, has 
been omitted for simplicity
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ALK1 or ALK5, respectively [76]. Finally, when coated to 
the substrate, purified endoglin is able to mediate binding 
to integrins, thus ruling out the potential involvement of 
endoglin-dependent intracellular signaling in these assays 
(Figs. 1, 4). Future studies may be needed to further assess 
the potential crosstalk between the TGF-β signaling pathway 
and endoglin-dependent binding to integrins.
The early formation of a blood cell plug to seal a dis-
rupted endothelial barrier is a repair mechanism whose 
alteration could play a critical role in vascular patholo-
gies such as HHT1. Although it is assumed that HHT1 is 
a vascular disease due to the fragility of the vessels, the 
involvement of an impaired mechanism of hemostasis when 
forming the blood cell plug cannot be excluded. As we pro-
vide evidence that endoglin plays a role in platelet adhesion 
on endothelium by interacting with integrins, an impaired 
adhesive function due to endoglin haploinsufficiency in 
EC might be involved in the associated bleeding in HHT1 
patients. This is in line with the finding that Eng+/− mice, a 
model for HHT1, have a prolonged bleeding time compared 
to controls (Eng+/+). Moreover, in HHT1 patients [11] and 
Eng+/− mice, the prothrombin time is similar to controls, 
suggesting a normal platelet-dependent extrinsic pathway 
of coagulation. Although many vascular disorders may lead 
to hemorrhage or thrombosis, it is often difficult to discern 
between a primary vascular defect/damage and a defect 
that has been induced by platelet activation/dysfunction or 
procoagulant abnormalities. Therefore, by deciphering the 
molecular mechanisms involved in HHT1-associated chronic 
bleedings, we may contribute to optimize current treatments 
and find novel therapeutic targets for other bleeding and/or 
thrombotic disorders.
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